Maintenance therapy for recurrent ovarian cancer after platinum treatment
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new drug, Raludotatug Deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as ongoing treatment after initial chemotherapy for recurrent ovarian cancer. It aims to see if this maintenance treatment helps keep the cancer from coming back longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult female (assigned female at birth).
- You must have high-grade (grade 3) serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer.
- You must have had two prior courses of platinum-based chemotherapy, and your cancer must have responded or not progressed after the most recent one.
- You must have a test result for BRCA or HRD (genetic markers related to cancer risk) from a validated test.
- You must be able to perform daily activities with minimal help (ECOG performance status 0 or 1).
- You must not be a candidate for PARP inhibitor maintenance therapy (a different type of maintenance treatment), according to your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
This trial tests a new drug called R-DXd (given alone or with another drug called bevacizumab) for ovarian cancer that has grown while on a PARP inhibitor. The goal is to see if this combination can help control the cancer.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This study tests a new drug called raludotatug deruxtecan for people with ovarian cancer that has come back. It's designed for those whose cancer is either sensitive or resistant to platinum chemotherapy, and who have had 1-3 prior treatments.
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Hear when a new Fallopian Tube Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.